# Prognostic and predictive imaging markers of hepatocellular carcinoma: a pictorial essay

**Authors:** Claudia Deyirmendjian, Banmeet Padda, Kathryn J. Fowler, Victoria Chernyak, Claude B. Sirlin, Hanyu Jiang, Kim-Nhien Vu, Joseph R. Dadour, Jessica Murphy-Lavallée, Jean-Sébastien Billiard, Damien Olivié, Bich N. Nguyen, An Tang

PMC · DOI: 10.1186/s13244-025-02058-7 · Insights into Imaging · 2025-08-15

## TL;DR

This paper reviews how imaging features can predict the aggressiveness and treatment response of hepatocellular carcinoma, offering insights for better clinical decision-making.

## Contribution

The paper compiles key imaging markers for HCC prognosis and treatment prediction, highlighting features not yet included in standard diagnostic systems.

## Key findings

- Imaging features like tumor size and low ADC correlate with microvascular invasion and poor prognosis.
- CT and MRI can distinguish between proliferative and non-proliferative HCC, aiding in treatment planning.
- Imaging can predict treatment responsiveness before therapy initiation, influencing therapeutic choices.

## Abstract

Hepatocellular carcinoma (HCC) encompasses a wide array of histopathologic and genetic features that can be broadly categorized as proliferative or non-proliferative HCC to reflect tumor aggressiveness. However, accurately characterizing tumor behavior remains challenging due to the biologic heterogeneity of HCC and limited access to tissue samples. Currently, imaging is used for the diagnosis of HCC using the Liver Imaging Reporting and Data System (LI-RADS) without histologic confirmation in most cases. Emerging data suggest that imaging can provide clinical insight beyond diagnosis and predict patient outcomes by identifying key prognostic features, including those not yet integrated in LI-RADS. Certain CT and MRI features correlate with proliferative and non-proliferative HCC, and may yield prognostic information. Imaging findings such as tumor size, multifocality, and low apparent diffusion coefficient (ADC) have also been associated with microvascular invasion—an independent marker of poor prognosis. Growing data support the role of imaging in predicting treatment responsiveness before therapy initiation, which may influence the selection of a therapeutic agent. The radiologist can offer key clinical information by understanding and describing the prognostic and predictive features in HCC imaging.

This study provides radiologists with a comprehensive summary of imaging findings associated with HCC prognosis, treatment responsiveness, and microvascular invasion.

Hepatocellular carcinoma (HCC) is a heterogeneous cancer leading to challenges in diagnosis and management.Tumors can exhibit imaging features associated with proliferative or non-proliferative HCC.Key imaging features can help predict tumor aggressiveness and treatment responsiveness before the therapy is applied.Further research leveraging molecular data and applying machine learning models can improve our understanding of HCC prognostication.

Hepatocellular carcinoma (HCC) is a heterogeneous cancer leading to challenges in diagnosis and management.

Tumors can exhibit imaging features associated with proliferative or non-proliferative HCC.

Key imaging features can help predict tumor aggressiveness and treatment responsiveness before the therapy is applied.

Further research leveraging molecular data and applying machine learning models can improve our understanding of HCC prognostication.

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, IMP3 (IMP U3 small nucleolar ribonucleoprotein 3) [NCBI Gene 55272] {aka BRMS2, C15orf12, MRPS4}, ABCC3 (ATP binding cassette subfamily C member 3) [NCBI Gene 8714] {aka ABC31, EST90757, MLP2, MOAT-D, MRP3, cMOAT2}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, AZIN2 (antizyme inhibitor 2) [NCBI Gene 113451] {aka ADC, AZIB1, ODC-p, ODC1L, ODCp}, ABCC1 (ATP binding cassette subfamily C member 1 (ABCC1 blood group)) [NCBI Gene 4363] {aka ABC29, ABCC, DFNA77, GS-X, MRP, MRP1}, SLCO1A2 (solute carrier organic anion transporter family member 1A2) [NCBI Gene 6579] {aka OATP, OATP-A, OATP1A2, SLC21A3}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, AXIN1 (axin 1) [NCBI Gene 8312] {aka AXIN, CMDOH, PPP1R49}, HEBP1 (heme binding protein 1) [NCBI Gene 50865] {aka HBP, HEBP}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, KRT19 (keratin 19) [NCBI Gene 3880] {aka CK19, K19, K1CS}
- **Diseases:** MASLD (MESH:D008107), autoimmune cirrhosis (MESH:D005355), tumorigenesis (MESH:D063646), Tumor necrosis (MESH:D009369), chronic hepatitis B viral infection (MESH:D014777), MVI (MESH:D017566), liver cirrhosis (MESH:D008103), metastasis (MESH:D009362), bleeding (MESH:D006470), biliary sepsis (MESH:D018805), fatty (MESH:D008067), calcification (MESH:D002114), Bile duct (MESH:D001649), liver tumors (MESH:D008113), ischemia (MESH:D007511), LI-RADS (MESH:D017093), Chronic (MESH:D002908), portal vein thrombosis (MESH:D012170), Metabolic dysfunction (MESH:D008659), Necrosis (MESH:D009336), ALD (MESH:D008108), Hepatocellular carcinoma (MESH:D006528), inflammation (MESH:D007249), hypoxia (MESH:D000860), deaths (MESH:D003643), autoimmune hepatitis (MESH:D019693), hepatocellular neoplasm (MESH:D018248), Bile duct tumor (MESH:D001650), Fat (MESH:D004620), MASH (MESH:D005234), hyperbilirubinemia (MESH:D006932)
- **Chemicals:** AP (-), gadoxetate disodium (MESH:C073590), H&amp;E (MESH:D006371), Fat (MESH:D005223), hematoxylin (MESH:D006416), alcohol (MESH:D000438), metal (MESH:D008670), copper (MESH:D003300), water (MESH:D014867), eosin (MESH:D004801), gadobenate dimeglumine (MESH:C064572)
- **Species:** Hepatitis B virus (no rank) [taxon 10407], hepatitis C virus [taxon 11103], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12356813/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12356813/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12356813/full.md

---
Source: https://tomesphere.com/paper/PMC12356813